08:00 , Dec 15, 2014 |  BioCentury  |  Finance

Avanir Chronicles

Avanir Chronicles...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Lidakol 10 percent n-docosanol data

LDAKA released additional results from a trial in 10 HIV-1 infected patients with KS (see BioCentury March 24, 1997). All 10 patients exhibited decreased lesion size after 3 months, and of 2 biopsies performed 1...
08:00 , Jan 16, 2006 |  BC Week In Review  |  Company News

Avanir Pharmaceuticals sales and marketing update

Avanir Pharmaceuticals (AVN), San Diego, Calif.   Business: Infectious   AVN granted an undisclosed company exclusive Japanese development and marketing rights to docosanol 10% cream to treat cold sores. AVN will receive a license fee,...
08:00 , Jan 16, 2006 |  BioCentury  |  Finance

Ebb & Flow

Drug Royalty Corp....
07:00 , Oct 11, 2004 |  BC Week In Review  |  Company News

Avanir, Aco Hud AB deal

Aco will exclusively manufacture and market AVN's docosanol 10% cream in Sweden, Norway, Denmark and Finland to treat cold sores. Aco plans to launch the product in 2005. Docosanol was approved in Sweden in 2003...
08:00 , Nov 24, 2003 |  BC Week In Review  |  Clinical News

Abreva docosanol 10% cream regulatory update

The Swedish Medical Products Agency approved docosanol 10% cream as a topical treatment for cold sore infections. Sweden will act as AVN's Reference Member State for the EU mutual recognition process. The company said it...
07:00 , May 5, 2003 |  BC Week In Review  |  Company News

Avanir, Drug Royalty deal

AVN received a $3.6 million payment from DRI under a 2002 deal in which AVN sold DRI a portion of its North American royalty stream on cold sore drug Abreva docosanol 10% cream. AVN said...
08:00 , Jan 6, 2003 |  BC Week In Review  |  Company News

Avanir Pharmaceuticals, Drug Royalty deal

AVN sold DRI a portion of its North American royalty stream on cold sore drug Abreva docosanol 10% cream. AVN retains rights to 50% of royalties earned on sales of Abreva in excess of $62...
08:00 , Jan 6, 2003 |  BioCentury  |  Finance

Ebb & Flow

Swiss venture capital firms HBM BioVentures and NMT New Medical Technologies are joining forces to create a firm with about CHF830 million ($640 million) under management. The merged firms, which both invest heavily in biotech...
08:00 , Dec 26, 2002 |  BC Extra  |  Company News

DRI gets rights to Avanir's Abreva royalties

AVN sold Drug Royalty Corp. (TSE:DRI) a portion of its North American royalty stream on cold sore drug Abreva docosanol 10% cream. AVN received an initial payment of $20.5 million, and is eligible for an...